
Cell & Gene Therapy Summit 2023
Enabling market access, policy, and delivery 24th-25th April 2023, Brussels
Newsletters and Deep Dive digital magazine
Enabling market access, policy, and delivery 24th-25th April 2023, Brussels
Approval in COPD could unlock a $3 billion market opportunity for the drug, say analysts.
Positive phase 2b results on liver fibrosis follow similar data with a rival drug from Akero.
ORION-17 study has been abandoned, with Novartis opting instead for a smaller global trial.
Pair of positive phase 3 studies means company will file for approval of zolbetuximab soon.
Editor's Picks
Newsletters and Deep Dive
digital magazine